GlassScriptPhysician profile
Edgardo J Aponte
NPI 1497718720
$4,005.65
in general payments reported to CMS, 2019-2025
37 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $211 · 2021: $479 · 2022: $494 · 2023: $841 · 2024: $711 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.56 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $608.48 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $598.24 | 2021-2025 | |
| Abbvie INC. | $457.23 | 2019-2025 | Liletta |
| Exact Sciences Corporation | $189.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $178.46 | 2019-2023 | |
| Amgen INC. | $164.23 | 2019-2025 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $162.64 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $134.40 | 2020-2025 | Slynd |
| Myriad Women'S Health, INC. | $117.88 | 2023 | Myrisk |
| Therapeuticsmd, INC. | $117.03 | 2019-2020 | |
| Evofem Biosciences, INC. | $100.81 | 2021-2022 | |
| Hologic Sales and Service, LLC | $99.75 | 2022-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Organon LLC | $92.82 | 2022-2025 | Nexplanon |
| Millicent US INC | $91.50 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Dysis Medical, INC. | $86.26 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $85.67 | 2019-2025 | |
| Daiichi Sankyo INC. | $79.81 | 2021-2024 | Injectafer |
| Myovant Sciences INC. | $77.58 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $77.23 | 2019-2021 | |
| Coopersurgical, INC. | $63.89 | 2019-2025 | Paragard T 380a |
| Ethicon US, LLC | $54.97 | 2021-2024 | Ethicon, Enseal |
| Merck Sharp & Dohme LLC | $47.65 | 2019-2023 | Gardasil 9 |
| Channel Medsystems, INC. | $37.44 | 2023 | |
| Renovia INC | $30.61 | 2021 | |
| Medtronic, INC. | $30.25 | 2023-2025 | Ligasure, Truclear |
| Avion Pharmaceuticals | $26.50 | 2023 | Balcoltra |
| Axonics, INC. | $26.19 | 2023 | Axonics |
| Mylan Pharmaceuticals INC. | $21.76 | 2019 | |
| Shield Therapeutics INC | $20.36 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $20.24 | 2022 | |
| Radius Health, INC. | $16.51 | 2019 | |
| Agile Therapeutics, INC. | $16.39 | 2021 | |
| Kci USA, INC. | $15.99 | 2021 | |
| Duchesnay USA Incorporated | $15.61 | 2019 | |
| Lupin INC. | $14.78 | 2020 | |
| Allergan, INC. | $14.19 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgardo Aponte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.